About 120 years ago, small towns argued over roads. Horses and bicycles were how we traveled. Some crazies thought horseless ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

With President Donald Trump back in the White House in 2025, it’s no surprise that he dominates the FactCheck.org year-end ...

Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.

A black-box warning is not a neutral informational update. It is the FDA’s most aggressive regulatory communication via product labeling, intended to alert clinicians and patients to risks so grave ...

The era of CureVac as an independent, publicly traded company has drawn to a close. BioNTech SE has successfully completed ...

As the immune system weakens with age, researchers have found a way to temporarily boost its function by reprogramming liver cells to support T-cell development.

The agency’s high-level turnover and conflicting policy decisions on drug oversight have fueled concerns about the leadership ...

A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts ...

While NIH director Jay Bhattacharya focuses on podcasting, his second in command is dramatically remaking the agency.

Changing just one atom in a COVID-19 vaccine lipid redirects delivery from the liver to the spleen, improving tumor ...

Can the weakened immune systems of older individuals be rejuvenated? Researchers from the German Cancer Research Center (DKFZ ...